Guardian Pharmacy Services, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data Guardian Pharmacy Services, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Revenue
1,228
1,449
Cost of revenue
984
1,156
Gross profit
244
293
Selling, general and administrative
307
220
Selling and marketing
3.5
3.9
Operating income
-62.9
72.7
Interest expense
3.28
0.67
Other non-operating income
-3.56
0.72
Pre-tax income
-66.5
73.4
Income tax
4.56
24.5
Net income to minority interests
16.3
-0.26
Net income
-110
49.2
EBITDA
-43.1
95
Balance sheet
FY2025
FY2025
Cash and equivalents
4.66
65.6
Receivables
97.2
102
Inventory
40.6
43.4
Other current assets
9.62
11
Total current assets
152
222
Property, plant and equipment
49.9
55.5
Lease right-of-use assets
29.1
34.6
Goodwill
69.3
79.7
Intangible assets
14.9
18.5
Other non-current assets
0.38
0.44
Total assets
321
413
Accounts payable
102
116
Accrued liabilities
14.4
15
Total current liabilities
144
161
Lease liabilities
23.3
30
Other non-current liabilities
3.42
4.04
Total liabilities
171
195
Total debt
0
0
Paid-in capital
125
139
Retained earnings
17.1
66.3
Minority interests
7.31
12.2
Total equity
150
218
Total liabilities and equity
321
413
Cash flow statement
FY2025
FY2025
Net income
-71
49
Depreciation and amortization
19.8
22.3
Stock-based compensation
131
13.9
Deferred income tax
0.7
3.07
Change in receivables
-25.5
-8.55
Change in inventory
-1.15
-0.88
Change in payables
13.2
16.4
Cash from operations
58
100
Capital expenditures
-14.7
-13.4
Cash from investing
-30.4
-32.2
Stock issued
120
29
Cash from financing
-23.6
-7.07
Net change in cash
3.91
61
Free cash flow
43.3
86.8
Interest paid
3.12
0.65
Income taxes paid
0
21.5
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2026; growth uses fiscal years. Valuation uses the share price of $50.11 on November 10, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
22.4%
Gross profit / revenue.
Operating margin
6.5%
Operating income / revenue.
EBITDA margin
8.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
7.2%
Pre-tax income / revenue.
Net margin
5.1%
Net income / revenue.
Operating cash flow margin
7.8%
Cash from operations / revenue.
Effective tax rate
27.7%
Income tax / pre-tax income, when pre-tax income is positive.
Return on assets (ROA)
15.2%
Net income / average total assets.
SG&A / revenue
16.0%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
0.6%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
1.6%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
17.9%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
19.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
73.0%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
100.8%
Free cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
28.6%
Total assets vs the same period a year earlier. Only from a positive base.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.65x
Current assets / current liabilities.
Quick ratio
1.27x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.67x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
43.1%
Total liabilities / total assets.
Interest coverage
145x
Operating income / interest expense.
Working capital
$115.7M
Current assets - current liabilities.
Goodwill and intangibles / assets
20.9%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
2.96x
Revenue / average total assets.
Fixed asset turnover
25.4x
Revenue / average property, plant and equipment.
Inventory turnover
19.8x
Cost of revenue / average inventory.
Days inventory
18 days
365 x average inventory / cost of revenue.
Receivables turnover
13.5x
Revenue / average receivables.
Days sales outstanding
27 days
365 x average receivables / revenue.
Days payables
41 days
365 x average accounts payable / cost of revenue.
Cash conversion cycle
5 days
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
$1.17
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Market cap + total debt - cash - short-term investments.
P/E
42.5x
Market cap / net income. Only when net income is positive.
P/S
2.18x
Market cap / revenue.
P/OCF
27.8x
Market cap / cash from operations, when positive.
EV/Sales
2.10x
Enterprise value / revenue.
EV/EBIT
32.4x
Enterprise value / operating income, when both are positive.
EV/EBITDA
26.0x
Enterprise value / EBITDA, when both are positive.
Earnings yield
2.4%
Net income / market cap (the inverse of P/E).
What was Guardian Pharmacy Services, Inc.'s revenue in fiscal 2025?
Guardian Pharmacy Services, Inc. reported revenue of $1.45B for fiscal 2025, 17.9% higher than the year before.
Was Guardian Pharmacy Services, Inc. profitable in fiscal 2025?
Yes. Net income was $49.2M, a net margin of 3.4%.
How much free cash flow did Guardian Pharmacy Services, Inc. generate in fiscal 2025?
Cash from operations of $100.3M minus capital expenditures of $13.4M left free cash flow of $86.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.